[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-343270-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-343270-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prmt1-inhibition-perturbs-rna-metabolism-and-induces-dna-damage-in-clear-cell-renal-cell-carcinoma-article-metadata","PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma - Article metadata","","PRMT1 inhibition is identified as a vulnerability in clear cell renal cell carcinoma (ccRCC). A chemical probe screen across patient-derived ccRCC models highlights MS023, a type I PRMT inhibitor, as antitumorigenic. Genetic knockdowns indicate PRMT1 as the critical dependency for cancer growth. MS023 treatment and PRMT1 depletion disrupt cell-cycle progression and DNA damage repair, while PRMT1 proteomics reveals RNA-binding–protein–rich interactions. These changes coincide with widespread mRNA metabolism defects, R-loop accumulation, and time-dependent DNA damage, supporting PRMT1 as a mechanistic translational target.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prmt1-inhibition-perturbs-rna-metabolism-and-induces-dna-damage-in-clear-cell-renal-cell-carcinoma-article-metadata/343270/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prmt1-inhibition-perturbs-rna-metabolism-and-induces-dna-damage-in-clear-cell-renal-cell-carcinoma-article-metadata/343270.png","ImageObject",300,407,{"name":42,"@type":43},"Miles","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the central finding about PRMT1 in clear cell renal cell carcinoma?","Question",{"text":63,"@type":64},"Inhibition of type I PRMTs reveals a vulnerability in ccRCC, and PRMT1 knockdown indicates PRMT1 is the specific critical dependency driving cancer growth.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which compound is used to inhibit PRMT1 activity in the study?",{"text":68,"@type":64},"MS023, a type I protein arginine methyltransferase inhibitor, is identified in the probe screen as antitumorigenic.",{"name":70,"@type":61,"acceptedAnswer":71},"How does PRMT1 inhibition or depletion lead to DNA damage?",{"text":72,"@type":64},"PRMT1-specific proteomics and downstream analyses indicate widespread disruptions in mRNA metabolism, including R-loop accumulation, which correlates with time-dependent DNA damage.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},343270,1790193066,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","Article [https://doi.org/10.1038/s41467-024-52507-y](https://doi.org/10.1038/s41467-024-52507-y)  \nPRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma  \nReceived: 13 April 2023  \n\n| Accepted: 9 September 2024 |\n| --- |\n| |\n| Check for updates |\n\nJoseph Walton 1,2, Angel S. N. Ng1,4, Karen Arevalo 1,4, Anthony Apostoli2, Jalna Meens2, Christina Karamboulas2, Jonathan St-Germain2,  \nPanagiotis Prinos 3, Julia Dmytryshyn2, Eric Chen 2,  \nCheryl H. Arrowsmith 1,2,3, Brian Raught1,2 & Laurie Ailles 1,2   \nIn addition to the ubiquitous loss of the VHL gene in clear cell renal cell carcinoma (ccRCC), co-deletions of chromatin-regulating genes are common drivers of tumorigenesis, suggesting potential vulnerability to epigenetic manipulation. A library of chemical probes targeting a spectrum of epigenetic regulators is screened using a panel ofccRCC models. MS023, a type I protein arginine methyltransferase (PRMT) inhibitor, is identiﬁed as an antitumorigenic agent. Individual knockdowns indicate PRMT1 as the speciﬁc critical dependency for cancer growth. Further analyses demonstrate impairments to cell cycle and DNA damage repair pathways upon MS023 treatment or PRMT1 knockdown. PRMT1-speciﬁc proteomics reveals an interactome rich in RNA binding proteins and further investigation indicates signiﬁcant widespread disruptions in mRNA metabolism with both MS023 treatment and PRMT1 knockdown, resulting in R-loop accumulation and DNA damage overtime. Our data supports PRMT1 as a target in ccRCCand informs a mechanismbased strategy for translational development.  \nThe clear cell subtype of renal cell carcinoma (ccRCC) is the most common malignancy to arise in the kidney and accounts for the majority of renal cancer-related deaths1. If detected early, localized tumors are surgically resected with the intent to cure2. However, many patients present with disseminated disease at the time of diagnosis3, and even with surgery disease recurrence is common4. The prognosis for metastatic ccRCC is poor. Five-year survival rates hover near 12%5 and, thanks to an insidious resistance to both radiation and cytotoxic chemotherapeutic agents, treatment options remain limited. It has been known for some time that biallelic inactivation of the von Hippel Lindau gene ( VHL) gene occurs in most cases of ccRCC, leading to complete loss of pVHL and a constitutive activation of the cell’s hypoxia response6. Although this appears to be a necessary and near universal driver event, evidence suggests that it alone is insufﬁcient to  \ninitiate tumorigenesis7–9. Recent, large-scale genomic analyses have revealed additional, frequent loss-of-function mutations in several key genes including PBRM1, SETD2, BAP1, KDM5C, KDM6A, MLL2, ARID1A and ARID1B10,11. There exists a surprising and common mechanistic theme to these additional putative tumor suppressor genes: their protein products are all involved in epigenomic regulation.  \nGiven the frequency of gene mutations impacting epigenetic regulatory proteins, and considering recent evidence from genetically engineered mouse models (GEMMs) that substantiate the importance of epigenetic regulators like PBRM1 and BAP1 in ccRCC tumor establishment12,13, we sought to identify epigenetic vulnerabilities that may be exploited to develop new therapies. To accomplish this, we performed an in vitro proliferative screen across a panel of patientderived ccRCC models14. We used a library of validated chemical  \n1Department of Medical Biophysics, University of Toronto, Toronto, ON, Canada. 2Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. 3Structural Genomics Consortium, University of Toronto, Toronto, ON, Canada. 4These authors contributed equally: Angel S. N. Ng, Karen Arevalo.  \n e-mail: [laurie.ailles@uhn.ca](laurie.ailles@uhn.ca)  \nprobes15,16 that selectively target a spectrum of epigenetic regulatory proteins. The results of our screen identiﬁed some pre","cbCaigm6Qpx88ALH","https://ap.wps.com/l/cbCaigm6Qpx88ALH","pdf",5961064,21,"English","# Background\n## VHL loss and epigenetic gene co-deletions in ccRCC\n# Screening strategy\n## Chemical probe screen in patient-derived models\n## Identification of PRMTs as dependencies\n# Mechanistic rationale\n## Arginine methylation and PRMT families\n# Experimental focus\n## Type I PRMT inhibition and PRMT1-mediated growth arrest\n## Downstream effects on RNA metabolism and DNA damage","[{\"question\":\"What is the central finding about PRMT1 in clear cell renal cell carcinoma?\",\"answer\":\"Inhibition of type I PRMTs reveals a vulnerability in ccRCC, and PRMT1 knockdown indicates PRMT1 is the specific critical dependency driving cancer growth.\"},{\"question\":\"Which compound is used to inhibit PRMT1 activity in the study?\",\"answer\":\"MS023, a type I protein arginine methyltransferase inhibitor, is identified in the probe screen as antitumorigenic.\"},{\"question\":\"How does PRMT1 inhibition or depletion lead to DNA damage?\",\"answer\":\"PRMT1-specific proteomics and downstream analyses indicate widespread disruptions in mRNA metabolism, including R-loop accumulation, which correlates with time-dependent DNA damage.\"}]","PRMT1 inhibition perturbs RNA metabolism and induces DNA damage in clear cell renal cell carcinoma - Article metadata | PDF",1790050524,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3c61b3414e4f47cc337b542ef109e1da.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e1485059757f3a3920b40e398618ecca.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b077c1d6fc070cedb0772ed6984187c0.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1a1a0d6ac5516f097a295c1dbca8569f.webp",980,1301]